A refresher on rubella

Background and epidemiology:
In March 2005 the US Centers for Disease Control and Prevention posted an early-release article online that announced the elimination of endemic rubella and congenital rubella syndrome (CRS) in the United States. The statement was based on the low number of reported rubella cases in that country (< 25 since 2001), the high vaccination coverage rate among school-aged children (> 95%), the high estimated population immunity (91%), the adequate surveillance system in place to detect rubella outbreaks and the pattern of virus genotypes consistent with virus origination in other parts of the world. The indigenous circulation of rubella in the United States has been interrupted thanks mostly to an established and effective vaccination program.

The rubella virus is a member of the Togaviridae family. Infection is acquired through contact or droplet transmission. The virus infects cells in the upper respiratory tract and replicates in the lymphoid system, after which a viremia leads to systemic infection involving many organs. In pregnant women, this includes the placenta, which puts the fetus at high risk of CRS. Transmission from infected people can occur up to 7 days before and 7 days after the onset of symptoms, especially rash. Up to 50% of cases are asymptomatic yet infectious, which is why an important component of managing a rubella outbreak involves identifying the epidemiologic links between potentially infected and exposed individuals.

In general, rubella is a mild illness. In children, constitutional features are mild or absent before the development of a transient rash, typically appearing 7–10 days after infection. Infected adults tend to experience more constitutional symptoms, and postpubertal women in particular are susceptible to lingering arthralgia. The most vulnerable, however, are fetuses, who are at high risk of CRS, particularly if exposed to the virus during the first 10 weeks of pregnancy. [Clinical features of CRS are listed in Box 1 of the article on page 1678 of this issue — Ed.]

Clinical management: Clinical diagnosis of rubella is unreliable. Laboratory confirmation to investigate IgG and IgM titres is essential for definitive diagnosis. In North America the differential diagnosis includes infection with human parvovirus B19, herpes virus 6, measles, West Nile virus and enterovirus. Pregnant women with rubella immunity should be reassured after exposure that reinfection is rare (< 5%) and the risk of CRS extremely low. Susceptible pregnant women who have been exposed to rubella should be followed clinically for signs and symptoms of infection, with serologic testing for IgM and IgG every 2 weeks for a 4-week period after the last exposure. Confirmation of rubella in the first trimester warrants consideration of pregnancy termination or, if this is unacceptable, referral to a high-risk obstetrics program.

Prevention: The rubella vaccine currently licensed for use in Canada incorporates live-attenuated virus strain RA27/3, prepared in human diploid cell culture. It is available most often in the trivalent vaccine for measles, mumps and rubella (MMR). Vaccination is very effective and stimulates an antibody response in over 97% of susceptible individuals. One dose is recommended for chil-
Children on or just after their first birthday; a second dose of MMR vaccine is administered before school entry, to maximize measles immunity. Women of childbearing age should be given rubella vaccine unless they have proof of immunity, and they should be advised to avoid pregnancy for 3 months after vaccination. Women from countries without good rubella vaccination programs (e.g., the former Soviet Union) may be particularly susceptible to infection. The vaccine is contraindicated in pregnant women and in immunocompromised people, although MMR vaccine is recommended for people with asymptomatic HIV infection. All suspected cases of rubella should be reported to the local medical officer of health so that urgent public health measures can be taken, especially active case ascertainment, identification and vaccination of susceptible contacts, and reduction of transmission in congregate settings through measures such as exclusion of nonimmunized students from school.

Erica Weir
CMAJ
Doug Sider
Associate Medical Officer of Health
Regional Niagara Public Health Department
Thorold, Ont.

References
1. Elimination of rubella and congenital rubella syndrome — United States, 1969–2004. MMWR Morb Mortal Wkly Rep 2005;54:279-82.
2. Banatvala J, Brown D. Rubella. Lancet 2004;363:1127-37.
3. Vaccine preventable diseases — rubella. Ottawa: Immunization and Respiratory Infections Division, Public Health Agency; 2002. Available: www.phac-aspc.gc.ca/dird-dimr/vpd-mev/rubella_e.html (accessed 2005 May 17).